Interval dosing with the HDAC inhibitor vorinostat effectively reverses HIV latency
- Archin, Nancie M.
- Kirchherr, Jennifer L.
- Sung, Julia A.M.
- Clutton, Genevieve
- Sholtis, Katherine
- Xu, Yinyan
- Allard, Brigitte
- Stuelke, Erin
- Kashuba, Angela D.
- Kuruc, Joann D.
- Eron, Joseph
- Gay, Cynthia L.
- Goonetilleke, Nilu
- Margolis, David M.
DOIAbstract
BACKGROUND. The histone deacetylase (HDAC) inhibitor vorinostat (VOR) can increase HIV RNA expression in vivo within resting CD4+ T cells of aviremic HIV+ individuals. However, while studies of VOR or other HDAC inhibitors have reported reversal of latency, none has demonstrated clearance of latent infection. We sought to identify the optimal dosing of VOR for effective serial reversal of HIV latency
Add to ORKG